FDA Approves First-in-Class Asundexian for Stroke Prevention

10 Nov 2026 0 comments

Asundexian becomes the first FDA-approved factor XIa inhibitor, offering a new option for preventing recurrent ischemic stroke when added to antiplatelet therapy.
Medscape Medical News

Source: Medscape Neurology Published 10 Nov 2026 Imported 10 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment